# 2026-04291: FDA Guides Industry on New Drug Exclusivity Perks

2026-04291, New Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug Products: Questions and Answers; Draft Guidance for Industry; Availability; Agency Information Collection Activities; Proposed Collection; Comment Request, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-03-04, effective Submit either electronic or written comments on the draft guidance by May 4, 2026 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance. Submit electronic or written comments on the proposed collection of information in the draft guidance by May 4, 2026.; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-04291
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-04291
- Title: New Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug Products: Questions and Answers; Draft Guidance for Industry; Availability; Agency Information Collection Activities; Proposed Collection; Comment Request
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 10617
- Published: 2026-03-04
- Effective: Submit either electronic or written comments on the draft guidance by May 4, 2026 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance. Submit electronic or written comments on the proposed collection of information in the draft guidance by May 4, 2026.
- Comments close: 2026-05-04
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Guides Industry on New Drug Exclusivity Perks

## Summary

The FDA just dropped a draft guide to help drug makers understand how to get 3-year exclusivity for new clinical studies on their drugs. This means companies can protect their new research from competition for three years, encouraging innovation. If you’re in the drug business, get your comments in by May 4, 2026, or risk missing out on shaping the final rules!

## Abstract

The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled "New Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug Products: Questions and Answers." This draft guidance is intended to assist applicants requesting New Clinical Investigation exclusivity (also referred to as 3-year exclusivity) for a new drug application (NDA) or NDA supplement. The guidance discusses the statutory and regulatory criteria for eligibility for 3-year exclusivity and provides recommendations on the content and format of requests for 3-year exclusivity in the form of questions and answers (Q&As). FDA intends to update this draft guidance document to include additional Q&As as appropriate.

## Effects PRIA read

- Draft guide explains 3‑year exclusivity: benefit, medium. The FDA published a draft guidance titled “New Clinical Investigation Exclusivity (3‑Year Exclusivity) for Drug Products: Questions and Answers” to help applicants request 3‑year exclusivity under 21 U.S.C. 355(c)(3)(E)(iii)-(iv) and 355(j)(5)(F)(iii)-(iv). The guidance explains the statutory and r…
- Template provided with no extra paperwork: benefit, low. The draft guidance includes a model template (in the Appendix) that FDA recommends applicants use to request New Clinical Investigation (3‑year) exclusivity. FDA tentatively concludes that providing the template “adds no further information collection requirements and imposes no further burden” bey…
- 3‑year exclusivity blocks certain approvals: cost, high. Under the cited statutory provisions (Hatch‑Waxman/section 505), a granted 3‑year New Clinical Investigation exclusivity means that 505(b)(2) applications and abbreviated new drug applications (505(j)/ANDAs) may not be approved for the exclusivity‑protected conditions of approval for three years af…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-04291 on federalregister.gov](https://www.federalregister.gov/documents/2026/03/04/2026-04291/new-clinical-investigation-exclusivity-3-year-exclusivity-for-drug-products-questions-and-answers)
- [2026-04291 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-03-04/pdf/2026-04291.pdf)

## Related
- [Previous: 2026-04290, Proposed Collection; Comment Request](https://policyrisk.com/federal-register/2026-04290)
- [Next: 2026-04292, Proposed Collection; Comment Request](https://policyrisk.com/federal-register/2026-04292)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-04291 (as of 2026-06-08).
